More on GILD
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $125.45 |
|
|||
| Open | $125.85 | ||||
| 52 Wk High | $108.63 | ||||
| 52 Wk Low | $71.39 | ||||
| Day High | $126.39 | ||||
| Day Low | $122.43 | ||||
| P/E | 68.38 | ||||
| EPS | $1.81 | ||||
| Volume | 14,348,344 | ||||
- Gilead Sciences (GILD) Reiterated at Overweight by Cantor Fitzgerald post CFO Chat
- Form 4 GILEAD SCIENCES, INC. For: Jun 15 Filed by: Mercier Johanna
- Form 4 GILEAD SCIENCES, INC. For: Jun 15 Filed by: Dickinson Andrew D
- Gilead Sciences (GILD) Reiterated at Overweight by Cantor Fitzgerald on FDA Approval
- Gilead Sciences: FDA accepts GILEAD application for once-weekly oral HIV prevention pill
- U.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention
- Form 144 GILEAD SCIENCES, INC. Filed by: Dickinson Andrew D
- Form 144 GILEAD SCIENCES, INC. Filed by: Mercier Johanna
- Gilead donates remdesivir to Uganda for Ebola outbreak response
- Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief
Entities mentioned with GILD
- Twitter | View Related Stories »
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Options | View Related Stories »
- Show More...
